Durability of antidepressant response to ketamine : systematic review and meta-analysis
Year: 2025
Type: dissertation
Study designs: Systematic Review, Meta-Analysis
Abstract: Major depressive disorder (MDD) is increasingly prevalent worldwide, and a significant portion of cases are treatment-resistant (TRD). Ketamine, long known as an anesthetic, has emerged as a novel rapid-acting antidepressant capable of producing robust early symptom relief. However, the overall rates of clinical response and the durability of ketamine’s antidepressant effects over time are not well established. A systematic review and meta-analysis was conducted to evaluate the durability of ketamine’s therapeutic effects in adults with MDD (including TRD) across acute and follow-up phases. Studies included randomized controlled trials and non-randomized controlled trials published of ketamine (and esketamine) in adults (≥18 years) with a DSM/ICD diagnosis of MDD. Data extraction was performed in duplicate. Outcomes were grouped by time: acute phase (1–14 days), early follow-up (15–55 days), and late follow-up (≥56 days). Random-effects models pooled response and remission proportions and standardized mean changes in depression scores (Hedges’ g). A total of 138 studies (n=6082 patients) met inclusion criteria; 106 (77%) involved treatment-resistant cohorts. The pooled clinical response rate was roughly 50% in the acute phase, rose to 59% in the 15–55 day follow-up, and was 48% at ≥56 days. Remission rates increased from 30% (acute) to 39% (early follow-up) and 52% (late follow-up). While pooled response rates showed no statistical significance, remission rates at acute and early follow-up were significant, heterogeneity was very high (I² generally >80%). The standardized mean reduction in depressive symptoms was large and significant at all times (SMD = –2.15 acute; –2.18 early; –2.49 late). Notably, in late follow-up analyses, studies with ≥6 ketamine sessions showed significantly lower response (36.5%) than those with <6 sessions (58.1%). Ketamine induces a strong antidepressant effect, but its sustained effect is inconsistent and highly variable. Fluctuations over time likely reflect study heterogeneity rather than systematic trends, and meta-regression identified no reliable predictors of sustained benefit. While some patients maintain improvement for weeks, effects beyond one month remain uncertain. Future studies should extend follow-up duration, standardize protocols, and explore predictors to identify likely responders. Combined approaches, such as adding psychotherapy, may enhance outcomes. In conclusion ketamine offers rapid relief in MDD and TRD patients, but its sustained benefit is unpredictable and should be interpreted with caution.
Author: Ruivo, Veronika Maria Cabeçana
Language: English
Subfield: Pharmacology (medical)
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W7111660401
